Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

E- PRISM: Precision Intervention Smoldering Myeloma: Phase II Trial of Combination of Elotuzumab, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Trial Profile

E- PRISM: Precision Intervention Smoldering Myeloma: Phase II Trial of Combination of Elotuzumab, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Elotuzumab (Primary) ; Lenalidomide (Primary)
  • Indications Smoldering multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 May 2023 Status changed from active, no longer recruiting to completed.
    • 13 Dec 2022 Results assessing immune biomarkers of progression performing single-cell RNA- and T-cell receptor sequencing using samples from 34 patients with high-risk smoldering multiple myeloma from this trial presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 14 Nov 2022 Results assessing Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma published in the Cancer Cell
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top